Senior Advocates Dayan Krishnan and Mohit Mathur appeared for the petitioner firm and argued that the FDA’s discover dated August 11, 2026, was despatched solely to the actors and to not the corporate itself, regardless of the petitioner being the one to endure irreparable hurt.
The corporate argued that the Maharashtra FDA lacked jurisdiction to problem instructions to halt the commercial.
In its petition, the corporate additionally said that surrogate commercial allegations have been baseless since Vimal pan masala has not been manufactured or bought in Maharashtra since 2001, and pan masala containing tobacco has been barred by the Supreme Courtroom nationwide since 2013.
The Courtroom was additionally instructed that the Central Shopper Safety Authority (CCPA) was already investigating comparable allegations and had issued no path in opposition to the marketing campaign.
